ABT-267: Phase III started

Enanta Pharmaceuticals Inc. (NASDAQ:ENTA, Watertown, Mass.) disclosed in its 4Q13 earnings that partner AbbVie began the open-label, Japanese Phase III GIFT-II trial to evaluate ABT-450 plus ritonavir, AbbVie's ABT-267 and ribavirin for 12 and 16 weeks in about 150 treatment-naïve and treatment-experienced patients with chronic HCV genotype 2 infection with and without compensated cirrhosis. ...